A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

Multiple sclerosis (Houndmills, Basingstoke, England)

Volumn 1, Issue 2, 1995, Pages 118-135

  Jacobs, L D ^a   Cookfair, D L ^a   Rudick, R A ^a   Herndon, R M ^a   Richert, J R ^a   Salazar, A M ^a   Fischer, J S ^a   Goodkin, D E ^a   Granger, C V ^a   Simon, J H ^a  

^a Millard Fillmore Gates Circle Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT SELECTION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0029311748     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859500100210     Document Type: Article

References (0)